Home / Companies / Aldeyra Therapeutics, Inc. / 4 Jun 2024
Aldeyra Therapeutics, Inc.: meeting of 4 Jun 2024
Votes reported on Form N-PX, item by item
174 Form N-PX filers reported votes at the Aldeyra Therapeutics, Inc. meeting of 4 Jun 2024. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
2 nominees; 22.9% of reported votes for; 56 filers withheld from or voted against at least one nominee.
218 vote records from 63 filers. 47 of the 63 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
237 vote records from 172 filers. 44 of the 166 filers that marked the item either way voted against management. 6 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
109 vote records from 63 filers. 0 of the 63 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | Abstain or withhold * | For | For |
| BlackRock and iShares | For | For | For |
| Fidelity | Split or no vote | For | For |
| Dimensional | Abstain or withhold * | Against * | For |
| State Street and SPDR | Abstain or withhold * | For | For |
| American Century | Abstain or withhold * | For | For |
| Invesco | Split or no vote | Against * | For |
| Equitable | For | For | For |
| Charles Schwab | Abstain or withhold * | For | For |
| Nuveen and TIAA | Abstain or withhold * | For | For |
| ProShares and ProFunds | Abstain or withhold * | For | For |
| John Hancock and Manulife | Abstain or withhold * | For | For |
| Morgan Stanley, Eaton Vance and Calvert | Abstain or withhold * | For | For |
| J.P. Morgan | No report | For | No report |
| Goldman Sachs | Split or no vote | For | For |
| PGIM and Prudential | No report | Against * | No report |
| Jackson National funds | Abstain or withhold * | Against * | For |
| Northern Trust and FlexShares | Split or no vote | For | For |
| SEI | Abstain or withhold * | Against * | For |
| T. Rowe Price | Abstain or withhold * | For | For |
| Lincoln Financial | Abstain or withhold * | For | For |
| Voya | Abstain or withhold * | For | For |
| Nationwide | Abstain or withhold * | For | For |
| Victory Capital | Abstain or withhold * | For | For |
| Brighthouse Funds | Abstain or withhold * | For | For |
| Guggenheim and Rydex | Abstain or withhold * | For | For |
| BNY Mellon | No report | Against * | No report |
| Principal | Abstain or withhold * | For | For |
| Pacific Life funds | For | For | For |
| Global X | Abstain or withhold * | Against * | For |
| AllianceBernstein | No report | For | No report |
| DWS | Abstain or withhold * | For | For |
| Janus Henderson | No report | For | No report |
| Neuberger Berman | No report | Against * | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Aldeyra Therapeutics, Inc. meeting?
174 Form N-PX filers reported votes at the meeting of 4 Jun 2024. On say-on-pay, 44 of 166 voted against management (26.5%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Aldeyra Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Aldeyra Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Aldeyra Therapeutics, Inc. with a meeting date within three days of 4 Jun 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.